BGES Bio Bridge Science Inc (CE)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One): [_] Form 10-K [_] Form 11-K [_] Form 20-F [X] Form 10-Q
 [_] Form N-SAR

 For Period Ended: June 30, 2008

[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR

For the Transition Period Ended:

Read attached instruction sheet before preparing form. Please print or
type.

Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I
REGISTRANT INFORMATION

PART II
RULE 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

[_] (a) The reasons described in reasonable detail in Part III of this form
 could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report |
 on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof
 will be filed on or before the 15th calendar day following the
 prescribed due date; or the subject quarterly report or transition
 report on Form 10-Q, or portion thereof will be filed on or before
 the fifth calendar day following the prescribed due date; and

[_] (c) The accountant's statement or other exhibit required by Rule
 12b-25(c) has been attached if applicable.

 PART III
 NARRATIVE

State below in reasonable detail the reasons why the Form 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The auditors are in the process of reviewing the report. We expect to file the required report within the allotted extension.

PART IV
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
[X] Yes [_] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
[_] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date August 14, 2008 By /s/ Dr. Liang Qiao
 ------------------- -----------------------------------------
 Dr. Liang Qiao
 Chief Executive Officer

Bio Bridge Science (CE) (USOTC:BGES)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Bio Bridge Science (CE) (USOTC:BGES)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024